Related Experiment Video

Updated: Oct 23, 2025

Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses
03:53

Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses

Published on: November 10, 2023

1.5K

Montelukast and Coronavirus Disease 2019: A Scoping Review

Niusha Sharifinejad1, Samin Sharafian2, Sana Salekmoghadam3

  • 1Student Research Committee, Alborz University of Medical Sciences, Karaj, Iran AND Alborz Office of Universal Scientific Education and Research Network (USERN), Alborz University of Medical Sciences, Karaj, Iran. marzieh.tavakol@yahoo.com.

Iranian Journal of Allergy, Asthma, and Immunology
|August 22, 2021
PubMed

Insights

Montelukast (MK), an asthma drug, shows potential as a treatment and preventative measure against SARS-CoV-2, the virus causing COVID-19. Further clinical trials are needed to confirm its effectiveness.

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Respiratory Medicine

Background:

  • Coronavirus disease 2019 (COVID-19) presents a significant global health challenge.
  • Developing effective therapeutic strategies against SARS-CoV-2 is crucial.
  • Montelukast (MK), a widely used asthma medication, has emerged as a potential antiviral agent.

Purpose of the Study:

  • To systematically review existing literature on the use of Montelukast (MK) in the treatment or prevention of COVID-19.
  • To evaluate the potential of MK as an adjuvant therapy or prophylactic agent against SARS-CoV-2.

Main Methods:

  • A systematic literature search was conducted across major scientific databases: PubMed, Web of Science, and Scopus.
  • Studies investigating the influence of MK on SARS-CoV-2 were identified and analyzed.
  • A total of 35 relevant studies were included in this review.

Main Results:

  • The reviewed studies suggest that Montelukast (MK) demonstrates potential benefits in managing COVID-19.
  • Evidence indicates MK may serve as a valuable adjuvant therapeutic agent.
  • MK also shows promise as a prophylactic measure against SARS-CoV-2 infection.

Conclusions:

  • Montelukast (MK) is a promising candidate for adjuvant therapy and prophylaxis against SARS-CoV-2.
  • The current evidence supports the consideration of MK in COVID-19 management strategies.
  • Further rigorous clinical trials are essential to definitively establish the efficacy and safety of MK for COVID-19.

Keywords:
COVID-19Leukotriene D4 receptorLeukotriene antagonistsMontelukastSARS-CoV-2

More Related Videos

Nasal Brushing Sampling and Processing Using Digital High Speed Ciliary Videomicroscopy – Adaptation for the COVID-19 Pandemic09:03

Nasal Brushing Sampling and Processing Using Digital High Speed Ciliary Videomicroscopy – Adaptation for the COVID-19 Pandemic

Published on: November 7, 2020

5.1K
Measuring Carbon Content in Airway Macrophages Exposed to Carbon-Containing Particulate Matters05:18

Measuring Carbon Content in Airway Macrophages Exposed to Carbon-Containing Particulate Matters

Published on: July 12, 2024

477

Related Concept Videos

Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
859
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
721
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.7K
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
3.4K
Asthma-III: Symptoms and Complications01:24

Asthma-III: Symptoms and Complications

Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
2.7K
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
492